Precigen Touts Encouraging Data From Autologous UltraCAR-T Cells Manufactured Overnight For Next Day Infusion In Ovarian Cancer
Portfolio Pulse from Vandana Singh
Precigen Inc presented encouraging data from the Phase 1 portion of the PRGN-3005 UltraCAR-T study in advanced-stage platinum-resistant ovarian cancer patients at the 2023 ASCO Annual Meeting. The treatment showed stable or partial response in 90% of target lesions, low incidence of TRAEs, and no neurotoxicity. PRGN-3005 is currently being evaluated in the Phase 1b dose expansion study.
June 06, 2023 | 3:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Precigen's PRGN-3005 UltraCAR-T showed encouraging results in a Phase 1 study for ovarian cancer patients, with 90% stable or partial response in target lesions and low TRAEs incidence.
The positive results from the Phase 1 study of PRGN-3005 UltraCAR-T in ovarian cancer patients indicate a potential breakthrough in treatment. This could lead to increased interest in Precigen's stock and a positive short-term impact on its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100